New therapeutic targets in atrophic age-related macular degeneration.
about
Compstatin: a complement inhibitor on its way to clinical applicationSystemic administration of Abeta mAb reduces retinal deposition of Abeta and activated complement C3 in age-related macular degeneration mouse modelCirculating Autoantibodies in Age-Related Macular Degeneration Recognize Human Macular Tissue Antigens Implicated in Autophagy, Immunomodulation, and Protection from Oxidative Stress and ApoptosisThe role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results.Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosisPharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment.Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.Effect of naringenin on NaIO(3)-induced retinal pigment epithelium degeneration and laser-induced choroidal neovascularization in rats.In pursuit of synthetic modulators for the orphan retina-specific nuclear receptor NR2E3Biological effects of cigarette smoke in cultured human retinal pigment epithelial cells.Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trialSphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degenerationBottlenecks in development of retinal therapeutic post-transcriptional gene silencing agentsRetinal pigment epithelium culture;a potential source of retinal stem cellsA1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesisUnfolding the Therapeutic Potential of Chemical Chaperones for Age-related Macular DegenerationBicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease.Citrullination of glial intermediate filaments is an early response in retinal injuryAge-related macular degeneration: experimental and emerging treatments.Preventive effect of Vaccinium uliginosum L. extract and its fractions on age-related macular degeneration and its action mechanisms.Bestrophinopathy: An RPE-photoreceptor interface disease.Impedance spectroscopy in monitoring the maturation of stem cell-derived retinal pigment epithelium.C5a, but not C3a, increases VEGF secretion in ARPE-19 human retinal pigment epithelial cells.The PI3K-PTEN tug-of-war, oxidative stress and retinal degeneration.A robust model for simultaneously inducing corneal neovascularization and retinal gliosis in the mouse eye.Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development.Human umbilical tissue-derived cells rescue retinal pigment epithelium dysfunction in retinal degeneration.MIF Inhibitor ISO-1 Protects Photoreceptors and Reduces Gliosis in Experimental Retinal Detachment.Progranulin increases phagocytosis by retinal pigment epithelial cells in culture.RPE phagocytic function declines in age-related macular degeneration and is rescued by human umbilical tissue derived cells.
P2860
Q24658454-79A1C783-1041-4D78-93E1-A3B39B4A6CADQ27316689-E1A2D836-399F-4A63-B51B-A381E3361708Q28551885-98E13A3E-8955-43B5-8D45-81AA2A192DBBQ33341287-CEE7C16D-96C7-4E71-8678-41AC7BD67640Q33748201-38A23988-C3A4-40A3-90B5-B1AA26129304Q34074393-94E172AD-D0C9-47F3-AE3E-BDC1A3D88D7EQ34243202-FC341A04-D5F6-4662-8E84-B5F770B7CA9DQ34254437-66181BA3-8255-4B1A-8C3C-DE4A1B04F181Q34457949-DF92C420-6BB8-4F74-8EA4-6F1C103BF64FQ34479008-0045E5F9-DD5A-4BCF-A8BF-86B04E6FA500Q34662112-8EFC3C42-DCD9-4C8F-AC3E-1970C5AEFFC6Q34678040-D8B19972-FF66-4762-8AD9-017FE3BC0986Q36071540-D51BCCBF-B849-43BB-9AEF-798A5613A899Q36400169-A0E6AADD-99CC-431A-88FD-65C297AAFCF0Q36530609-3B65B337-54A7-4930-8DB2-EDE7E1C91E03Q36697237-F043AF1B-B990-4930-AF6A-FC121CEAC5A6Q36992465-FA0E1991-69A9-47C3-8758-91A20E13C261Q37292700-EC4A4210-FC3F-4869-BB43-EE13749C0C84Q37577435-2BBBB6CE-8D03-4314-A3EB-F386184679D7Q38818001-92677B5B-079E-4872-BA09-65AF1B5BFD19Q39098224-90CE0D9F-B4A3-42D5-8CD5-9F8C3383693BQ39476810-1258C2E4-6C8B-4736-BF25-A2EE7D81A93EQ39890415-13AB4832-EAFD-482C-9360-B6FD54941251Q41460864-97C77845-EDEA-4F8E-9348-05B2592B8046Q42844151-A73C698A-A6ED-49BD-960E-B27FEAD0F38FQ45870879-609191CA-1A6D-4398-926E-3CFB19BE0274Q46651920-68CAE773-AAE3-4D4E-BC25-E9C798E57D3AQ47586517-E375538F-D4BA-46A9-A661-93CC8429EB00Q48137804-88840EE1-C67D-4AFD-88F1-8EA2DFF68A8BQ52657629-3CF8F0A7-3859-4244-911B-32EA32E7A416
P2860
New therapeutic targets in atrophic age-related macular degeneration.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
New therapeutic targets in atrophic age-related macular degeneration.
@ast
New therapeutic targets in atrophic age-related macular degeneration.
@en
type
label
New therapeutic targets in atrophic age-related macular degeneration.
@ast
New therapeutic targets in atrophic age-related macular degeneration.
@en
prefLabel
New therapeutic targets in atrophic age-related macular degeneration.
@ast
New therapeutic targets in atrophic age-related macular degeneration.
@en
P2860
P1476
New therapeutic targets in atrophic age-related macular degeneration.
@en
P2093
Konstantin Petrukhin
P2860
P304
P356
10.1517/14728222.11.5.625
P407
P577
2007-05-01T00:00:00Z